AMENDMENTS TO THE CLAIMS

1. (currently amended) A method of preventing breast cancer in a mammal which comprises administering to a mammal in need of such prevention an effective amount of a compound of the formula I:



I

wherein:

A is ~~selected from~~ CH_2 ~~and NR~~;

B, D and E are ~~independently selected from~~ CH ~~and N~~;

Y is

(a) phenyl, optionally substituted with 1-3 substituents independently selected from R^4;

(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R^4;

(c) C_3-C_8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R^4; or

(d) C_3-C_8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R^4;

~~(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, NR^2- and $-S(O)_n-$, optionally substituted with 1-3 substituents independently selected from R^4;~~

~~(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, NR^2- and $-S(O)_n-$ optionally substituted with 1-3 substituents independently selected from R^4; or~~

~~(g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR³-, NR²- and -S(O)$_n$-, optionally substituted with 1-3 substituents independently selected from R⁴;~~

Z^1 is

~~(a) -(CH$_2$)$_p$W(CH$_2$)$_q$-;~~

~~(b)~~ (a) -O(CH$_2$)$_p$ CR^{5}R^6-;

~~(c)~~ (b) -O(CH$_2$)$_p$W(CH$_2$)$_q$-; or

~~(d)~~ (c) -OCHR^{2}CHR^3-; ~~or~~

~~(e) -SCHR²CHR³-;~~

G is



~~(a) NR^{7}R^8;~~

~~(b)~~



~~wherein n is 0, 1 or 2; m is 1, 2 or 3; Z² is -NH-, -O-, -S-, or -CH$_2$-; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R⁴; or~~

~~(c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R⁴;~~

~~Z⁴ and G in combination may be~~



W is

(a) $-CH_2-$;

(b) -CH=CH-;

(c) -O-;

(d) $-NR^2-$;

(e) $-S(O)_n-$;

(f)

(g) $-CR^2(OH)-$;

(h) $-CONR^2-$;

(i) $-NR^2CO-$;

(j)



; or

(k)  ;

R is hydrogen or C_1-C_6 alkyl;

R^2 and R^3 are independently

(a) hydrogen; or

(b) C_1-C_4 alkyl;

R^4 is

(a) hydrogen;

(b) halogen;

(c) C_1-C_6 alkyl;

(d) C_1-C_4 alkoxy;

(e) C_1-C_4 acyloxy;

(f) C_1-C_4 alkylthio;

(g) C_1-C_4 alkylsulfinyl;

(h) C_1-C_4 alkylsulfonyl;

(i) hydroxy (C_1-C_4)alkyl;

(j) aryl (C_1-C_4)alkyl;

(k) -CO_2H;

(l) -CN;

(m) -CONHOR;

(n) -SO_2NHR;

(o) -NH_2;

(p) C_1-C_4 alkylamino;

(q) C_1-C_4 dialkylamino;

(r) -$NHSO_2$R;

(s) -NO_2;

(t) -aryl; or

(u) -OH.

R^5 and R^6 are independently C_1-C_8 alkyl or together form a C_3-C_{10} carbocyclic ring;

~~R^7 and R^8 are independently~~

~~(a) phenyl;~~

~~(b) a C_3-C_{10} carbocyclic ring, saturated or unsaturated;~~

~~(c) a C_3-C_{10} heterocyclic ring containing up to two heteroatoms, selected from -O-, -N- and -S-;~~

~~(d) -H;~~

~~(e) C_1-C_6 alkyl; or~~

~~(f) form a 3 to 8 membered nitrogen containing ring with R^5 or R^6;~~

~~R^7 and R^8 in either linear or ring form may optionally be substituted with up to three substituents independently selected from C_1-C_6 alkyl, halogen, alkoxy, hydroxy and carboxy;~~

~~a ring formed by R^7 and R^8 may be optionally fused to a phenyl ring;~~

e is ~~0,~~ 1 ~~or 2~~;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 0, 1, 2 or 3;

q is 0, 1, 2 or 3;

~~and optical and geometric isomers thereof; and nontoxic pharmacologically acceptable acid addition salts, N-oxides, esters, and quaternary ammonium salts thereof~~

or an optical or geometric isomer thereof; or a nontoxic pharmacologically acceptable acid addition salt, N-oxide, ester or quaternary ammonium salt thereof.

2. (currently amended) A The method of claim 1 wherein the compound is a compound of the formula:



3. (original) A method of preventing breast cancer in a mammal which comprises administering to a mammal in need of such prevention an effective amount of (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol, or a nontoxic pharmacologically acceptable acid addition salt, N-oxide, ester, or quaternary ammonium salt thereof.

4. (original) A method of preventing breast cancer in a mammal which comprises administering to a mammal in need of such prevention an effective amount of *Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol, or an optical or geometric isomer thereof; or a nontoxic pharmacologically acceptable acid addition salt, N-oxide, ester, or quaternary ammonium salt thereof.

5. (new) The method of claim 3 wherein (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is administered to the mammal.

6. (new) The method of claim 3 wherein the mammal is a human.

7. (new) The method of claim 6 wherein the human is female.

8. (new) The method of claim 5 wherein the amount of (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is a unit dosage of 0.1 mg to 50 mg administered to the mammal once to four times a day.

9. (new) The method of claim 8 wherein the amount of (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is a unit dosage of 0.25 mg to 25 mg administered to the mammal once to four times a day.

10. (new) The method of claim 9 wherein the (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is administered to the mammal once a day.

11. (new) The method of claim 10 wherein the mammal is human.

12. (new) The method of claim 11 wherein the human is female.